Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

Abstract

Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer [RAW_REF_TEXT] Liying Ma1,2,3 na1, [/RAW_REF_TEXT] [RAW_REF_TEXT] Xing Bian1,2,3 na1 & [/RAW_REF_TEXT] [RAW_REF_TEXT] Wenchu Lin 1,3 [/RAW_REF_TEXT] Journal of Experimental & Clinical Cancer Research volume 40, Article number: 7 (2021) Cite this article [RAW_REF_TEXT] 93 Accesses [/RAW_REF_TEXT] [RAW_REF_TEXT] Metrics details [/RAW_REF_TEXT] [RAW_REF_TEXT] The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:219 [/RAW_REF_TEXT] Correction to: J Exp Clin Cancer Res (2020) 39:219 https://doi.org/10.1186/s13046-020-01728-2 Following the publication of the original article [1], it was noted that the representative images of Rad51 immunofluorescence staining of H82 cell line in the original Figure 5A of this article were presented incorrectly. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer [RAW_REF_TEXT] Liying Ma1,2,3 na1, Xing Bian1,2,3 na1 & Wenchu Lin 1,3 [/RAW_REF_TEXT] Journal of Experimental & Clinical Cancer Research volume 40, Article number: 7 (2021) Cite this article [RAW_REF_TEXT] 93 Accesses Metrics details The original article was published in Journal of Experimental & Clinical Cancer Research 2020 39:219